Phase II/III Study for Evaluation of the Diagnostic Performance of [18F]CTT1057 PET Imaging for the Detection of PSMA Positive Tumors Using Histopathology as a Standard of Truth
Latest Information Update: 02 Jun 2024
At a glance
- Drugs 18F-CTT 1057 (Primary)
- Indications Prostate cancer
- Focus Diagnostic use; Registrational
- Acronyms GuideView
- Sponsors Novartis Pharmaceuticals
- 21 Feb 2024 Status changed from recruiting to completed.
- 17 Nov 2023 Planned End Date changed from 30 Nov 2023 to 28 Nov 2023.
- 17 Nov 2023 Planned primary completion date changed from 16 Nov 2023 to 28 Nov 2023.